STAT3 and ovarian cancer: Indeed, raised levels of IL-6 in ascites and serum from ovarian cancer patients correlate with cisplatin and paclitaxel resistance and poor disease prognosis [259], whereas blockade of STAT3 expression in ovarian cancer cells increases their sensitivity to paclitaxel [254].